Navigation Links
Rudy Mazzocchi Joins the Greatbatch Board of Directors as he Continues to Expand his Presence in the Med-tech Industry
Date:1/22/2013

Orlando, FL (PRWEB) January 22, 2013

As a serial entrepreneur with his grass-roots training in LifeScience Alley, the heartland of medical device companies in Minnesota, it’s no surprise that Rudy Mazzocchi continues to surface in the national and local headlines. Greatbatch, Inc. (NYSE:GB), a developer and manufacturer of implantable medical technologies for the cardiac, neurology, vascular, and orthopaedic markets, announced that Mazzocchi has been elected to its Board of Directors where he will also serve on the Board’s Technology Development & Innovation and Corporate Governance & Nominating Committees.

Another recent article in the prestigious Minneapolis/St. Paul Business Journal highlights his track record in establishing various medical device companies which were later successfully acquired and integrated into multi-billion dollar companies. What might surprise the readers of this business journal is that while building, managing and financing nearly a dozen start-up companies, Mazzocchi also managed to rack up a few literary awards for his latest suspense novel, EQUITY of EVIL. Based on the average Customer Reviews, EQUITY of EVIL is currently ranked the #1 Medical Thriller on Amazon.

Mazzocchi will be the first to emphasize that his primary focus relates to his current “day job” as Chief Executive Officer of ELENZA, Inc.; a venture-backed ophthalmic device company that is developing the world’s first electro-active AutoFocal Intraocular Lens for patients affected by cataracts. This proprietary technology is intended to offer the patient an implantable lens that replaces the aging “cloudy” natural lens with a programmable, autofocusing acrylic lens that contains its own rechargeable power source, biosensors and programmable microchips. ELENZA is completing its Swiss-based development efforts and transitioning into a production phase in order to initiate clinical studies for European commercial approval in 2014-2015.

When asked “what’s next?”, his audience needs to retake their seat. Mazzocchi will tell-a-tale of how the expansive platform of his ELENZA technology has enormous applications not only inside the eye, but for other active implants throughout the body. He’ll then jump to a story about another patented idea that is being developed in collaboration at the Florida Institute of Technology (Melbourne, FL); one that was designed to help repair the damaged eyes of his younger brother and thousands of others suffering from the same clinical problem. Mazzocchi will then end with an animated description of his next novel, EQUITY of FEAR, anticipated for release in February of 2013.

Mazzocchi’s BIO:

Rudy is best known as a medical device and biotechnology entrepreneur, inventor, and angel investor, with a history of starting new technology ventures throughout the U.S. and Europe. He’s been privileged to have the opportunity to see the newest innovations in healthcare and work with some of the most brilliant researchers, scientists and physicians in the industry.

Authoring more than 50 patents, he has helped pioneer new companies involved in cardiology, oncology, orthopedics, neurosurgery and even embryonic stem-cell development. Through these efforts, he has become the recipient of many technology and business awards, including the aforementioned Ernst & Young Entrepreneur of the Year in Healthcare and the Businessman of the Year Award.

Combining these experiences and opportunities, with thousands of hours of travel and long evenings in hotel rooms, he found the initiative to start writing a collection of medical thrillers based on true events, now referred to as The EQUITY Series.

Read the full story at http://www.prweb.com/releases/2013/1/prweb10233491.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Rudy Mazzocchi Prepares to Release the Second Thriller in The EQUITY Series Trilogy, entitled EQUITY of FEAR
2. Diabetes Research Institute Foundation’s (DRIF) CEO Joins Healthcare Holdings Group, Inc. Board of Directors
3. IntelliCell BioSciences Announces Michael Hershman Joins the IntelliCell BioSciences Board of Directors
4. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
5. John A. Orwin Joins Array BioPharma Board Of Directors
6. IntelliCell BioSciences Announces Myron Z. Holubiak Joins the IntelliCell BioSciences Board of Directors
7. MD Anderson Cancer Center joins Actinium Pharmaceuticals (API) Multicenter Actimab-A Trial
8. Walgreens Joins with Ferring Pharmaceuticals Inc. to Offer Products and Resources to Women Facing Fertility Complications from Cancer Treatment
9. Northwestern University Joins VIVO Network with Elseviers SciVal Experts
10. New Physician Joins Dallas Based Fertility Center
11. Maxx Performance Joins GreenPalm to Promote Sustainable Harvest of Palm Oil
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)...  GenomOncology today announced the appointment of Joshua F. ... Dr. Coleman will oversee clinical content development and ... The GenomOncology software suite empowers molecular pathologists with a seamless ... decision support, from quality control through reporting. ... , , ...
(Date:11/30/2016)... 2016  The Allen Institute for Cell Science ... publicly available collection of gene edited, fluorescently tagged ... cellular structures with unprecedented clarity. Distributed through the ... are a crucial first step toward visualizing the ... makes human cells healthy and what goes wrong ...
(Date:11/30/2016)... 30. November 2016   Merck , ... die Unterzeichnung einer Reihe von Vereinbarungen mit ... Evotec AG Screeningleistungen für Mercks Palette genetischer ... Zugriff auf diese Bibliotheken in Kombination mit ... schnelleren Weg zur Ermittlung und Erforschung neuer ...
(Date:11/30/2016)... (PRWEB) , ... November 30, 2016 , ... ... sources for advanced technology applications, introduces the 5th generation, ultra-bright, Laser-Driven Light Source, ... successful Laser-Driven Light Source (LDLS™) technology, the EQ-77 offers higher radiance and irradiance ...
Breaking Biology Technology:
(Date:11/14/2016)... Inc. ("xG" or the "Company") (Nasdaq: XGTI, XGTIW), a ... challenging operating environments, announced its results for the third ... conference call to discuss these results on November 15, ... Key Recent Accomplishments The ... Vislink Communication Systems. The purchase is expected to close ...
(Date:6/27/2016)... Research and Markets has announced the addition ... to their offering. The report ... to grow at a CAGR of 12.28% during the period 2016-2020. ... in-depth market analysis with inputs from industry experts. The report covers ... The report also includes a discussion of the key vendors operating ...
(Date:6/22/2016)... , June 22, 2016   ... management and verification solutions, has partnered with ... software solutions for Visitor Management, Self-Service Kiosks ... provides products that add functional enhancements to ... provides corporations and venues with an automated ...
Breaking Biology News(10 mins):